Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.840
+0.020 (0.71%)
At close: Apr 20, 2026, 4:00 PM EDT
2.850
+0.010 (0.35%)
Pre-market: Apr 21, 2026, 5:52 AM EDT
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of 8.00, which predicts a 181.69% increase from the current stock price of 2.84.
Price Target: $8.00 (+181.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +181.69% | Mar 26, 2026 |
| BTIG | BTIG | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +181.69% | Mar 16, 2026 |
| BTIG | BTIG | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +146.48% | Jan 27, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +181.69% | Nov 18, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +216.90% | Aug 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.45
from -2.00
EPS Next Year
-1.23
from -1.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.29 | -1.06 | |
| Avg | -1.45 | -1.23 | |
| Low | -1.59 | -1.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.